Mesoblast (NASDAQ:MESO) Sees Strong Trading Volume – Should You Buy?

Mesoblast Limited (NASDAQ:MESO) shares saw an uptick in trading volume on Thursday . 1,283,734 shares changed hands during trading, an increase of 78% from the previous session’s volume of 722,881 shares.The stock last traded at $15.00 and had previously closed at $12.25.

Analyst Ratings Changes

Several research firms have weighed in on MESO. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Tuesday, September 24th. Jefferies Financial Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating in a research note on Thursday, August 29th. StockNews.com downgraded shares of Mesoblast from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research report on Thursday, August 29th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Mesoblast Stock Up 35.4 %

The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The firm’s 50-day moving average is $10.24 and its 200-day moving average is $8.17.

Hedge Funds Weigh In On Mesoblast

A number of large investors have recently modified their holdings of MESO. Perkins Coie Trust Co grew its holdings in shares of Mesoblast by 15.0% in the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after purchasing an additional 1,500 shares during the last quarter. Signaturefd LLC grew its holdings in Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after acquiring an additional 3,099 shares during the last quarter. Lazari Capital Management Inc. increased its position in shares of Mesoblast by 6.6% in the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock valued at $364,000 after acquiring an additional 3,300 shares during the period. Pine Valley Investments Ltd Liability Co bought a new position in shares of Mesoblast during the second quarter valued at about $80,000. Finally, Rathbones Group PLC purchased a new stake in shares of Mesoblast during the second quarter worth about $95,000. 1.43% of the stock is owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.